Key Highlights
- Shares of Soleno Therapeutics (SLNO) jumped more than 30% during premarket hours Monday following acquisition rumors
- Neurocrine Biosciences (NBIX) is reportedly nearing a deal to purchase Soleno in a transaction exceeding $2.5 billion
- The proposed acquisition could price SLNO shares in the low-to-mid $50 range
- According to the Financial Times, an agreement may be reached as early as Monday, April 6
- Shares of Neurocrine declined 0.4% premarket following the announcement
Soleno Therapeutics has experienced a challenging start to 2026, with shares declining approximately 14% since the year began — until Monday morning brought dramatic change.
Soleno Therapeutics, Inc., SLNO
According to a Financial Times report, Neurocrine Biosciences has entered late-stage negotiations to acquire the rare disease-focused biotech company in a transaction valued at over $2.5 billion. News of the potential buyout propelled SLNO shares upward by more than 30% before the market opened.
The proposed transaction would place Soleno’s valuation in the low-to-mid $50s per share. According to the FT report, negotiations are accelerating rapidly, with a potential announcement possible as soon as Monday.
Soleno’s primary therapeutic product is Vykat XR, which the company brought to market last year for treating hyperphagia — a medical condition associated with Prader-Willi syndrome. This condition triggers unrelenting, excessive hunger that can result in severe health complications such as gastric rupture, choking hazards, obesity, and heart disease.
Prader-Willi syndrome affects approximately one in 15,000 births, making it a rare genetic condition. Vykat XR represents the first approved and commercialized treatment specifically targeting the hunger-related manifestations of this syndrome.
Industry analysts have projected that Vykat XR could achieve peak yearly revenues reaching $2.3 billion — a projection that appears to have drawn significant interest from Neurocrine.
Neurocrine Expands Into Rare Disease Territory
Neurocrine Biosciences currently maintains a market valuation of approximately $13.21 billion. The company’s existing product lineup features Ingrezza, designed to treat involuntary movement disorders associated with Huntington’s disease, alongside multiple other commercialized therapies and developmental candidates.
Acquiring Vykat XR would establish Neurocrine’s presence in the rare disease and orphan drug sector, where companies typically enjoy robust pricing capabilities and face minimal competitive pressure.
Shares of Neurocrine slipped 0.4% in premarket activity Monday. This modest decline represents a common market response when acquiring companies announce major purchases — investors factor in the premium costs associated with the transaction.
Understanding SLNO’s Recent Performance
Despite Monday’s substantial premarket gains, SLNO had fallen roughly 14% in 2026 prior to this week. The stock had underperformed despite favorable analyst sentiment regarding Vykat XR’s market opportunity.
According to TipRanks data, SLNO carries a Strong Buy rating based on consensus from 11 analysts. The mean price target stands at $101.09, while the most optimistic projection reaches $125.
If the acquisition closes at the reported valuation range of low-to-mid $50s per share, the deal would price Soleno significantly beneath those analyst projections — though it would still deliver a notable premium compared to the company’s recent trading levels.
The Financial Times report referenced individuals with knowledge of the negotiations, indicating that discussions are advancing smoothly and accelerating toward a possible final agreement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
